Table 1.

Participant demographics.

Characteristics	Participant group
	Patients with MS (N = 72)	Healthy volunteers (N = 80)
Median age	44	38
Age range	20–79	23–73
Male	19	19
Female	53	61
Relapse-remitting	62	N/A
Primary progressive	2	N/A
Secondary progressive	7	N/A
Disease-modifying therapies*	46	N/A

OS, Left eye; OD, Right eye.

*These include: Fingolimod, Tecfidera, Dimethylfumerate, Copaxone, Plegridy, Alemtuzimab and Tysabri. One MS participant’s disease subtype was unable to be determined from their electronic correspondence.